BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hou JL, Jia JD, Wei L, Zhao W, Wang YM, Cheng M, Tang X, Tan DM, Ren H, Tang H, Cohen D, Llamoso C. Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China. J Viral Hepat 2013;20:811-20. [PMID: 23876210 DOI: 10.1111/jvh.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Xu Y, Wu XN, Shi YW, Wei W, Yang AT, Sun YM, Zhao WS, You H. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis. Chin Med J (Engl) 2015;128:1867-72. [PMID: 26168824 DOI: 10.4103/0366-6999.160488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Aljumah AA, Bin Selayem NA, Al-Howti SY, Dafallah M, AlGhamdi H, Mokhtar H, Albekairy AM, Sanai FM. Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience. J Infect Chemother 2019;25:12-6. [PMID: 30366861 DOI: 10.1016/j.jiac.2018.09.014] [Reference Citation Analysis]
3 Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Ray Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 2016;43:134-44. [PMID: 26510638 DOI: 10.1111/apt.13440] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
4 Desalegn H, Aberra H, Berhe N, Mekasha B, Stene-Johansen K, Krarup H, Pereira AP, Gundersen SG, Johannessen A. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Med 2018;16:234. [PMID: 30554571 DOI: 10.1186/s12916-018-1229-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
5 Kim CW, Kim CS, Kim HY, Lee CD, Yu K, Llamoso C, Lee HJ. Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Korean J Intern Med 2018;33:91-101. [PMID: 29228519 DOI: 10.3904/kjim.2016.111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
7 Cuenca-Gómez JÁ, Lozano-Serrano AB, Cabezas-Fernández MT, Soriano-Pérez MJ, Vázquez-Villegas J, Estévez-Escobar M, Cabeza-Barrera I, Salas-Coronas J. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice. BMC Infect Dis 2018;18:568. [PMID: 30428845 DOI: 10.1186/s12879-018-3469-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Lim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. J Clin Transl Hepatol 2020;8:377-84. [PMID: 33447520 DOI: 10.14218/JCTH.2020.00039] [Reference Citation Analysis]
9 Wang Y, Wang M, Zhang G, Ou X, Ma H, You H, Jia J. Control of Chronic Hepatitis B in China: Perspective of Diagnosis and Treatment. China CDC Wkly 2020;2:596-600. [PMID: 34594716 DOI: 10.46234/ccdcw2020.159] [Reference Citation Analysis]